Skip to content

Study · Animal study (in vivo) · pig · 2004

6 results

The role of melanocortin-3 and -4 receptor in regulating appetite, energy homeostasis and neuroendocrine function in the pig.

Barb CR, Robertson AS, Barrett JB, Kraeling RR, Houseknecht KL

The Journal of endocrinology1 Apr 2004Cited by 32 (Europe PMC)

PMID15072565 (opens in a new tab)DOI10.1677/joe.0.1810039 (opens in a new tab)PepBankPUB-15072565
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In growing pigs, intracerebroventricular NDP-MSH suppressed feed intake compared with controls at 12, 24, 48 and 72 h after treatment (P<0.05).

    In plain wordsIn growing pigs, NDP-MSH given into the brain reduced feed intake compared with controls for up to three days.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseFeed intake
    Study

    pign: not reported in source

    Comparator
    Controls
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (pig).

    Source sentences

    Summary
    i.c.v. administration of an MC3/4-R agonist, NDP-MSH, suppressed (P<0.05) feed intake compared with controls at 12, 24, 48 and 72 h after treatment in growing pigs.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pigs, fed animals were more responsive to the MC3/4-R agonist NDP-MSH than fasted animals.

    In plain wordsIn pigs, fed animals reacted more to NDP-MSH than fasted animals.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseFeed intake response in fed versus fasted pigs
    Study

    pign: not reported in source

    Comparator
    Fasted pigs
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (pig).

    Source sentences

    Summary
    Fed pigs were more responsive to the MC3/4-R agonist then fasted animals.
    1 context sentence
    Summary · context
    i.c.v. administration of an MC3/4-R agonist, NDP-MSH, suppressed (P<0.05) feed intake compared with controls at 12, 24, 48 and 72 h after treatment in growing pigs
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pigs, NDP-MSH across a wide dose range failed to affect LH secretion.

    In plain wordsIn pigs, NDP-MSH did not change LH secretion across a wide dose range.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeLH secretion
    Study

    pign: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (pig).

    Source sentences

    Summary
    Treatment with NDP-MSH or SHU9119, across a wide dose range, failed to affect LH and GH secretion, except for the 10 micro g dose of NDP-MSH, which exhibited both a stimulatory and an inhibitory effect on GH secretion in fasted animals.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In pigs, NDP-MSH across a wide dose range failed to affect GH secretion, except for the 10 micro g dose.

    In plain wordsIn pigs, NDP-MSH did not change GH secretion, apart from one dose.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeGH secretion across a wide dose range
    Study

    pign: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (pig).

    Source sentences

    Summary
    Treatment with NDP-MSH or SHU9119, across a wide dose range, failed to affect LH and GH secretion, except for the 10 micro g dose of NDP-MSH, which exhibited both a stimulatory and an inhibitory effect on GH secretion in fasted animals.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In fasted pigs, the 10 micro g dose of NDP-MSH had both a stimulatory and an inhibitory effect on GH secretion.

    In plain wordsIn fasted pigs, one NDP-MSH dose both raised and lowered GH secretion.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    MixedGH secretion at the 10 micro g dose in fasted animals
    Study

    pign: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 micro g · intracerebroventricularAs given in this study (pig).

    Source sentences

    Summary
    except for the 10 micro g dose of NDP-MSH, which exhibited both a stimulatory and an inhibitory effect on GH secretion in fasted animals.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 06LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Mechanism

    In HEK293 cells expressing the porcine MC4-R sequence, SHU9119 blocked the NDP-MSH-induced increase in cAMP.

    In plain wordsIn cells with the pig MC4 receptor, SHU9119 blocked the cAMP rise that NDP-MSH caused.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseNDP-MSH-induced cAMP increase with SHU9119
    Study

    n: not reported in source

    HEK293 cells expressing porcine MC4-R
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    SHU9119 blocked the NDP-MSH-induced increase in cAMP in HEK293 cells expressing the porcine MC4-R sequence without the missense mutation.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.